Radiopharmaceutical company AdvanCell has received $18 million from the Medical Research Future Fund (MRFF) to develop and deliver targeted alpha therapies for prostate cancer, which is the second ...

SYDNEY--(BUSINESS WIRE)--AdvanCell, a clinical-stage radiopharmaceutical company developing innovative cancer therapeutics, today announced $18M in Australian Federal Government Funding from the ...

In other radiopharmaceuticals news, Sydney, Australia-based AdvanCell announced in February 2025 that it had successfully completed an oversubscribed, $112 million round of Series C financing (2). The ...

Cancer treatment start-up AdvanCell’s raised $171 million and Aravax raised $66 million to help grow its allergy symptom reduction products. The average deal size rose to an all-time high over ...

The company also represents Advancell expandable microspheres and S-LEC BK polyvinyl acetal resins. Sekisui Specialty Chemicals is a subsidiary of the Sekisui Chemical Group, a multibillion dollar ...

Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span oncology, diabetes, immunology ...

All Lines Technology, announced that CRN, a brand of The Channel Company, has recognized All Lines Technology on its 2025 Tech Elite 250 list. This annual list highlights solution providers based ...

While biotech and medtech startups dominated total capital raised — buoyed by a $179 million raise by Harrison.ai and a $178.6 million round for cancer treatment startup AdvanCell — AI edged ...